Received: 12 February 2026 Accepted: 22 February 2026 Published Date: 28 February 2026

ScienceFrontier
OPEN ACCESS

Biomedical Research and Clinical Advancements
ISSN Online: 3065-341X

Review ARTICLE

Antiviral therapies for hepatitis C infection: current and new developments

Hari Prasad Sonwani*

Apollo College of Pharmacy, Anjora Durg 491001(C.G),India

***Corresponding Author:** Hari Prasad Sonwani. *Apollo College of Pharmacy, Anjora Durg 491001(C.G),India*

Citation: Hari Prasad Sonwani (2026). Antiviral therapies for hepatitis C infection: current and new developments, J *Biomedical Research and Clinical Advancements*; 3 (1) 42, **DOI:** *BRCA-RA-26-42*

Abstract:

The majority of HCV strains in Europe and North America are genotype-1, and up to 75% of individuals with chronic infection can be cured with recently approved direct acting antivirals. New antiviral treatments offer longer treatment durations, better tolerability, increased virological response, and possibly even the opportunity to stop using interferon. The primary treatment drugs, such as telaprevir and boceprevir, that are currently part of the standard of care are highlighted in this study. It then assesses the mechanisms underlying newly developed medications, as well as the response rates observed in existing research. Lastly, it looks ahead to the not-too-distant future to examine treatment plans that include interferon-free medicines and agent combinations, and in which patients They could end up being the most successful.

Key words: antiviral therapy; direct acting antiviral; hepatitis C virus; polymerase inhibitors; protease inhibitors

Introduction:

Hepatitis C virus (HCV), which infects around 170 million individuals worldwide, is the primary cause of liver transplants and the second most common cause of liver cancer. 1-3. HCV recently overtook HIV in terms of deaths that could be attributed to it in the United States, while obtaining less attention than other blood-borne viruses. 4. Viral elimination can prevent the consequences of chronic hepatitis C (CHC) infection. For the past ten years, ribavirin (RBV) and peginterferon-alpha (PEG-IFN) have been the standard of care treatments. Regretfully, only 50% of patients infected with genotype-1 HCV—the most common strain of HCV in Europe and North America—will be cured with PEG-IFN and RBV. Significant toxicities, such as psychological morbidity, influenza-like symptoms, and cytopenias, may restrict use and necessitate cautious patient selection and observing 5-8. When combined with PEG-IFN and RBV, the recently approved directly acting drugs (DAA) for HCV, boceprevir and telaprevir, significantly increase efficacy and can cure up to 75% of patients with genotype-1 HCV who have a chronic infection. New antiviral treatments offer longer treatment durations, better tolerability, increased virological response, and possibly even the option to stop using IFN. The two recently released DAAs, telaprevir and boceprevir, are included in this review along with an overview of the primary therapeutic drugs utilized in the current standard of care and their limitations. It assesses the mechanisms of the most promising new medications, describing their response and development stage, and focusing on the next generation of HCV protease inhibitors, HCV polymerase inhibitors, NS5A inhibitors, and cyclophilin inhibitors rates observed thus far in clinical trials. Lastly, it looks forward to a time when customized treatment plans incorporating drug combinations and interferon-free therapy would be discussed, along with which patients might benefit most from them.

Peginterferon-alpha and ribavirin (RBV) are the cornerstones of modern HCV therapy.

Prior to 2011, PEG-IFN and RBV were the standard of care for treating chronic HCV infection, and they still are for non-genotype-1 HCV. In patients who have not received therapy, the sustained viral response (SVR) for HCV genotype-1 infection is approximately 45%, while genotypes -2 and -3 infection result in 75% SVR rates in genotype-1 can now reach up to 75% thanks to the introduction of telaprevir and boceprevir therapy; nonetheless, PEG-INF/RBV remains crucial in preventing the establishment of resistance-associated HCV genotypes. When PEG-IFN monotherapy is used, treatment response rates for acute HCV infection are quite high, ranging from 70–90% SVR rates. Regretfully, acute HCV infection typically shows no symptoms, and the diagnosis is not established until Chronicity is proven. IFN-based therapy is frequently contraindicated by comorbidities in the small percentage of individuals with acute diagnoses IFN contains antiviral properties that are both direct and indirect. Interferon-stimulated genes are induced to produce effector proteins and cytokines that prevent virus replication and provide an antiviral state, hence mediating direct effects. Major Histocompatibility Complex class 1 genes are up-regulated in antigen-presenting cells, which results in the cytotoxic T-cell clearance of HCV-infected cells, mediating indirect effects. 7. When covalently linked to interferon, polyethylene glycol (PEG) polymer chains decrease renal and hepatic clearance, enable weekly delivery, and exhibit higher sustained vector recall compared to conventional interferon 12, 13.

Ribavirin's mode of action for treating HCV is not fully known. There are several theories. According to viral kinetic research, HCV mutagenesis resulting in mistake catastrophe and a subsequent decline in HCV fitness is an a crucial action mechanism 8, 14. Another guanosine analogue, RBV has the potential to function as a chain terminator by integrating ribavirin into the HCV genome during viral replication 8. As with viral infection, ribavirin may also alter host T-cell immunity.

PEG-IFN/RBV side effects are frequent and a significant drawback of the available treatments. Important adverse effects of PEG-IFN include weariness, mental illness, suppression of the bone marrow, and influenza-like symptoms. 6, 7. A thorough patient selection and monitoring process is necessary due to potential psychiatric adverse effects, such as depression or aggressiveness, which may prevent some patients from receiving existing PEG-IFN based therapy. Anaemia and hemolysis are caused by ribavirin. In the context of cirrhosis, 8 and on-treatment cytopaenias caused by both drugs are more frequent. Creating HCV treatment plans that are less harmful is clinically significant and ought to increase the number of patients who are qualified for care and who successfully complete therapy.

Predictors of the responsiveness to IFN-based therapy

The outcome of PEG-IFN/RBV treatment is significantly predicted by the host's genetic makeup. A variation in the IL-28B gene area has been linked to a better response to HCV treatment, according to genome-wide studies 15, 16. People with a favorable IL-28B genotype respond to PEG-IFN/RBV two to three times more frequently 17, 18. Pre-treatment viral load, the degree of liver fibrosis, and insulin resistance are additional significant predictors of PEG-IFN response 19. The most reliable indicator of SVR is the virological response during treatment, and the amount of time it takes for viral clearance has been used to determine whether to continue treatment (response-guided therapy, or RGT) or not. Regardless of HCV genotype, a rapid virological response (RVR, undetectable HCV RNA at week 4) is 86–100% predictive of SVR 20 is reached in roughly 64–76% of genotype-2/-3 infections and 10–27% of genotype-1 infections. 21. Short-term therapy may be an option for patients who obtain an RVR and have a low baseline virus load. SVR 20 is 68–84% common in genotype-1 individuals who achieve complete early virological response (EVR, undetectable HCV RVA at week 12). Patients may be evaluated for prolonged PEG-IFN/RBV therapy if their virological drop is gradual but sustained. HCV RNA levels at weeks 12 and 24 are crucial for forecasting treatment failure. If, at week 12, HCV RNA has decreased by less than 2 log10 IU/ml−1 or is still detectable at week 24, treatment should be stopped, as 1-3 SVR is expected. 22, 23. When initial therapy fails, the success percentage of PEG-IFN/RBV retreatment has been unsatisfactory, with a meta-analysis estimating a pooled SVR of 16%. 24. Relapsers with genotype-1 infection who were previously "relapsed," or who achieved an undetectable HCV RNA at the end of treatment but did not achieve an SVR, have a 15–25% SVR rate after further treatment. Upon retreatment, genotype-1 previous "null-responders," who were described as having a reduction in HCV RNA viral load of less than 2 log10 IU/ml after 12 weeks of medication, had a 4- 14% SVR 25, 26. The efficiency of PEG-IFN/RBV treatment is slightly decreased in the presence of HIV co-infection: the APRICOT trial found that the SVR for genotype-1 infection was 29%, while the SVR for genotype-2/-3 infection was 62%. On the other hand, drug use through injection does not influence the outcome of treatment. A systematic study of PEG-IFN/RBV for chronic HCV treatment found that the median SVR was 54% (range 18%-94%) among drug injectors, compared to 54%–63% among non-injectors (28). Those who use narcotics can also benefit from acute HCV treatment 29. There is a need for improvements in treatment efficacy, as evidenced by the moderate effectiveness of PEG-IFN/RBV for chronic HCV treatment and the lower SVR in individuals with severe liver disease who previously failed therapy and HIV co-infection.

Novel and developing antiviral treatment with direct action

Numerous novel treatment drugs that directly target enzymes have been developed as a result of a better knowledge of HCV replication (Figure 1). The RNA genome of the flavivirus HCV codes for a polyprote in 30. Translation occurs to create the structural polyprotein after HCV reaches hepatocytes; this polyprotein needs to be broken into functional proteins 31. These intracellular activities are mediated by a number of non-structural proteins (NS2-NS5), which have shown promise as DAA therapeutic targets 32, 33. Antagomir targeting miR-122 and cyclophilin inhibitors, a host enzyme directly engaged in HCV replication, are examples of host target inhibitors. While they provide an anti-viral state, novel immunomodulators, new interferons, or ribavirin analogues are not HCV specific. A recent comprehensive analysis discovered more than There are presently 50 compounds being developed to treat chronic HCV, spread across 34 different treatment classes. We have chosen the most promising molecules from each major class as examples of medications under development, taking into account the quickly changing body of literature It is important to remember that the majority of these medications are still in the early phases of development, have only been presented at conferences, and have only been examined in small cohorts. Consequently, care must be taken while interpreting their findings.



Figure 1: HCV viral life cycle and therapeutic targets for new drug classes (A) HCV virus binding and entry via receptor-mediated endocytosis (targeted by entry inhibitors); (B) RNA release into the cytoplasm; (C) Translation into a polypeptide on the ribosome, and processing into viral proteins that form structural components of the virus (targeted by protease inhibitors); (D) RNA replication in the endoplasmic reticulum (targeted by protease, polymerase, NS5A and cyclophilin inhibitors, and antagomirs); (E) RNA packaging and assembly (targeted by NS5A inhibitors); and (F) virion maturation and release (targeted by glycosylation inhibitors).

HCV protease inhibitors available now

Boceprevir and telaprevir, two HCV protease inhibitors (PIs), are currently approved for the long-term treatment of HCV. The HCV viral polyprotein is broken down into mature proteins by the HCV non-structural (NS)-3/4A HCV protease. By reversibly binding to the NS3 active site, both medications inhibit polyprotein cleavage and stop HCV replication 35. Apart from its direct antiviral effect, NS3 protease inhibition may also have the function of reinstating the hepatocyte interferon-signalling pathways 36. Both medications have limited effectiveness against other HCV genotypes and were developed utilizing genotype-1 HCV-specific in vitro methods. When boceprevir and telaprevir are administered alone, virological resistance quickly develops 37, 38, requiring combination with PEG-IFN/RBV. Triple therapy with boceprevir or telaprevir showed noticeably higher rates of SVR in pivotal trials compared with PEG-IFN/RBV in individuals with HCV genotype-1 infection who were both treatment-naïve and treatment-experienced.

Boceprevir

In individuals with genotype-1 HCV infection, boteceprevir treatment consists of 800 mg (4 × 200 mg) of oral capsules given every 8 hours after a 4-week lead-in of standard PEG-IFN/RBV therapy. Patients who have not started treatment are given boceprevir along with PEG-IFN/RBV 35 for a further 24 weeks (if HCV RNA was not detected by week 8) or 44 weeks (if HCV RNA was detected by week 8). Following the 4-week PEG-IFN/RBV lead-in 39, treatment-experienced patients get the same dose for 44 weeks. Lowering HCV RNA levels before starting boceprevir treatment made sense because it would lessen the chance of viral breakthrough or resistance 40. The lead-in facilitates the evaluation of IFN responsiveness; if HCV RNA falls below <1 log10 IU/ml−1, week 4: 5% is the expected SVR while using PEG-IFN/RBV alone, compared to 29–39% when boceprevir is added. When boceprevir was introduced to PEG-IFN/RBV, treatment-naïve patients' SVR improved from 40% to 67–68% in non-Black patients and from 23% to 42–53% in Black patients (Table 1). Additionally, 44% of patients were eligible for short-term therapy with RGT. Patients on boceprevir experienced anemia almost twice as frequently as controls (49% vs. 29%), but the likelihood of therapy discontinuation due to adverse events did not differ statistically (35). Patients on boceprevir were more likely to utilize erythropoietin to treat anemia (43% vs. 24%). Additionally, dysgeusia was observed in boceprevir patients over twice as frequently as in controls (37% vs. 18%). Among those who had previously Boceprevir increased SVR from 7% to 52% among partial responders 39 and from 29% to 75% among prior relapsers who had failed PEG-IFN/RBV. With boceprevir therapy, the SVR rate for previous null responders was 38% 41. Both the boceprevir 35, 39 and the telaprevir 42, 43 registration studies were well-powered, randomized control trials with good design. Their primary drawback is the trial's generalizability to clinical settings. First off, based on week 4 RVR, boceprevir's trial design with its 4-week lead-in phase has an advantage in terms of overall outcome prediction. In actuality, though, the lead-in adds to the complexity of therapy. Second, the use of erythropoietin to treat anemia during therapy may have contributed to the high rates of treatment completion and matching high SVR rates for both PIs. trials that may not be accessible outside of a study setting in more than 40% of individuals. Lastly, contrasted to the 9–14 percent rate observed in the clinical trials of boceprevir and telaprevir, new results from a French observational cohort on the use of HCV PIs in clinical practice revealed substantial rates of major side events (38–49%) 44. On the other hand, information regarding whether the SVR seen in studies would vary in real life is currently lacking.

Telaprevir

In patients who are new to treatment, the telaprevir treatment paradigm is the oral administration of 750 mg (2 × 375 mg) capsules for 12 weeks, followed by the concurrent administration of PEG-IFN for 24 weeks (with RVR and EVR) or 48 weeks (for patients who do not reach EVR). In the registration trial, PEG-IFN/RBV for 24–48 weeks together with 8 or 12 weeks of telaprevir treatment increased SVR in previously untreated patients from 44% to 69–75% 43. In the telaprevir-treated groups, rash and anemia were more common, and treatment discontinuation was more common (7–11% telaprevir group vs. 3% control group). Eczematous rashes were the most common type and disappeared when telaprevir was stopped. Nonetheless, there has only been one documented instance of DRESS syndrome with Stevens-Johnson syndrome. The usage of erythropoietin was prohibited. gastrointestinal side When compared to controls, telaprevir side effects (nausea, diarrhea, anorectal discomfort, and hemorrhoids) were considerably more common (40–43% vs. 31%).

In HCV genotype-1 patients who have previously failed PEG-IFN/RBV, telaprevir also increases SVR rates. When telaprevir was administered for 12 weeks together with 48 weeks of PEG-IFN/RBV, either with or without a 4-week lead-in phase, the SVR of previous relapsers increased from 24% to 83–88%, that of partial responders from 15% to 54–59%, and that of null responders from 5% to 29–33% 42. When treated with either telaprevir (62% vs. 33%) or boceprevir (50% vs. 39%, non-Black cohort) combination therapy, patients with cirrhosis showed significantly better SVR; nevertheless, treatment toxicities were more problematic, with higher discontinuation rates (15% vs. 11% among non-cirrhotics). 45. Rash, in a sub-analysis of the registration study for telaprevir, Patients with cirrhosis experienced pruritus and anemia at higher rates (43%, 55%, and 44%, respectively) compared to those who got PEG-IFN/RBV (27%, 35%, and 27%, respectively).

Drug interactions with protease inhibitors

The complexity of treatment is increased by drug interactions between HCV PIs and other prescriptions. HCV PIs appear to inhibit CYP34A strongly and reversibly. Nevertheless, additional information suggests that the metabolism and excretion of boceprevir 46 use a different non-CYP34A route. When other cytochrome P450-metabolized medications, such as HIV combination antiretroviral therapy, are administered concurrently, PI concentrations can change. This has significant consequences for patients who are co-infected with HIV and HCV 47.

New protease inhibitors for HCV

In phase II/III trials, several novel NS3A PIs are being developed in addition to telaprevir and boceprevir. The once-daily dosed TMC-435 PI is anticipated to be the next to hit the market; it has an advantage over the NS3/4A PIs that are now on the market. TMC-435 combined with PEG-IFN/RBV was utilized in a phase II trial of treatment-naïve, genotype-1 patients for 48 weeks of treatment in total, with weeks 4 through 20 being guided by HCV RNA. Of the patients, 68–76% attained RVR, and 88–95% attained SVR 48. Between 79 and 86% of patients qualified for short-term (24-week) treatment. The overall virological response in this cohort may have been overestimated because the study's control group likewise had a strong SVR response. When compared to the control group, it exhibited a favorable side effect profile with comparable incidences of rash and anemia. A strong second generation NS3 PI in the early stages of development is MK-5712. It works effectively against HCV genotypes 1–6 in vitro and just needs to be taken once daily 49. Additionally, MK-5172 exhibits efficacy against some genotypes that exhibit resistance to certain protease inhibitors under development A number of additional PIs are being developed Regardless of any further increase in SVR, these new PIs will probably replace the first generation PIs due to their improved side effect profile and ease of use.

NS5B polymerase inhibitors for HCV

Nucleoside inhibitors (NI) and non-nucleoside inhibitors (NNIs) are two categories into which NS5B polymerase inhibitors fall. Because the HCV catalytic site is conserved across genotypes, NIs are effective and active against all HCV genotypes. Their resistance profile is strong, and HCV genotypes resistant to NI have shown extremely low fitness thus far (50). GS-7977, which has started phase III development for genotype-1 HCV in conjunction with PEG-IFN/RBV 51–53, is currently the most promising NI. Additionally, GS-7977 has advanced to phase III development as an IFN-free genotype-2/-3 therapy. HCV (see below). Another NI in advanced clinical development is merimericabine. In one research, response-guided mericitabine plus PEG-IFN/RBV or PEG-IFN/RBV alone was administered for at least 24 weeks to patients who were treatment-naive and infected with HCV genotypes 1/-4. The intervention group's virological response at 12 weeks post-treatment (SVR12) was 76%, while the standard therapy group's SVR12 was 56%. Several phase II investigations have verified its antiviral potency (91% RVR) 55. NNIs cause conformational changes and downregulate the activity of the polymerase by binding to allosteric regions surrounding the NS5B enzyme's active site. A number of NNIs have advanced to the clinical stage, such as tegobuvir, which is in phase II development. Others, such as filibuvir 56 and silibinin 57, are at early stages of development. The NNIs' class-wide restrictions on among them are their comparatively low potency and the quick development of resistance. They might play a part in DAA combination regimens.

HCV NS5A inhibitors

Strong, all-around antivirals are NS5A replication complex inhibitors. Strong NS5A inhibitor daclatsavir is effective for treating patients with HCV genotype-1, regardless of experience level 58, 59. Daclatasvir administered in conjunction with PEG-IFN/RBV vs. standard therapy showed an SVR12 of 83–92% vs. 25%, respectively, in a phase II study of patients who were not yet receiving treatment 59. Gene bank studies have discovered natural variants at the HCV NS5A gene that confer daclatasvir resistance, and these polymorphisms have been demonstrated to be clinically relevant in vivo 60. The potential effects of these main resistance mutations on the NS5A class are being investigated further.

DAA and HCV resistance are related treatment

Naturally occurring resistance-associated variants (RAVs) 50 are caused by the high replication rate and error-prone HCV polymerase. RAVs are chosen in a matter of days when PI monotherapy is used, which results in virological breakthrough 61. The R155/A156 alterations are cross-resistant for all PIs, and single nucleotide substitutions linked to resistance to all PIs in development have been found. Using PEG-IFN/RBV in combination can stop mutants from appearing 62, 63. As a result, phase III PI trials now under progress include triple therapy with PEG-IFN and RBV.

Inhibitors of the host target

Inhibitors of cyclophilins

Since cyclophilin A is necessary for HCV replication, cyclophilin inhibitors, including several of them, have been developed 54. By attaching to the host protein, cyclophilin A 64, alisporivir (Debio025), a typical, non-immunosuppressive ciclosporin analogue, prevents HCV assembly and replication. Patients who were not yet on therapy for HCV genotype-1 in a phase II trial showed higher SVR (76%) with alisporivir plus PEG-IFN/RBV compared to PEG-IFN/RBV alone (55%). 65. Phase III development of alisporivir for HCV genotype-1 is currently underway. Additionally active against HCV genotypes 2/-3 is alisporivir, and IFN-free regimens are presently under investigation. Although it has been documented, resistance to cyclophilin inhibitors is believed to be uncommon in vivo 66.

Antagomirs

Hepatocyte HCV buildup requires the expression of microRNA-122 (miR-122), which is expressed by the liver 67. An oligonucleotide complementary to miR-122, referred to be a "antagomir," resulted in a protracted decrease of HCV viraemia in animal models. In an early phase II trial, patients with HCV genotype-1 received weekly subcutaneous weight-based injections of miravirsen, a miR-122 antagonist, for one month, after which they received conventional therapy 68. After the conclusion of active therapy, a sustained and ongoing antiviral activity was seen with little adverse effects.

Immunomodulators

Immunomodulatory drugs enhance innate immune responses, which in turn aids in the indirect removal of HCV. When used in conjunction with normal therapy, nitazoxanide, an anti-parasitic drug, increases surface expression of interferon (SVR) 69. In a phase II research, nitazoxanide was utilized as a 4-week lead-in, followed by treatment with emollient therapy in individuals primarily with HCV genotype-4 36 weeks of PEG-IFN, either with or without ribavirin. With or without ribavirin, the SVR was 79% vs. 61%, respectively. However, nitazoxanide 69 patients saw higher side effects.
By facilitating endogenous interferon and cytokine release 70, toll-like receptor (TLR)-7 and TLR-9 stimulation can trigger anti-HCV action. Currently in phase II development, a small chemical inducer of the TLR-7 pathway shows antiviral activity of −1.3 log10 IU ml−1 from baseline, compared with −0.3 log10 IU ml−1 in the placebo group 71. Additionally, a TLR-9 agonist has finished phase-1 development 72. In the early stages of development are also therapeutic vaccine targets. In phase II investigations of genotype-1, one vaccination agent (GI-5005) which produces a protein spanning HCV NS3 and core protein sequences showed antiviral effectiveness were combined to PEG-IFN/RBV, increasing SVR from 48% to 58% in treatment-naïve individuals 73, 74.

Alternative therapeutic modalities

Numerous innovative indirectly acting antivirals are being developed at different phases. Their primary benefit is that they do not cause viral resistance due to their non-specific action; but, if used in combination with other medications, they might complicate treatment.

Interferon substitutes

Research has been done on substitute interferon medicines to increase their effectiveness and tolerance. Because PEG-IFN-lambda targets a more hepatocyte-specific receptor and is efficacious against all HCV genotypes, it has fewer hematological adverse effects. Fewer dose reductions of interferon, less marrow toxicity and flu-like symptoms, and an overall improvement in the fast virological response (varying from 40-71% based on HCV genotype) 75 were observed in a phase II research. Every two weeks, Alb interferon is prepared using PEG-IFN-alpha coupled to albumin to extend its half-life and so lessen adverse effects. Despite the fact that non-responders with genotypes 1-3 had an SVR of 51%, development has been abandoned 76.

Analogs of ribavirin

The main purpose of studying ribavirin analogues instead of ribavirin is to lessen ribavirin-associated anemia 77. Taribavirin is a prodrug that lessens in red blood cell accumulation and targets the liver preferentially. In a phase III research, PEG-IFN plus taribavirin showed a significant reduction in anemia when compared to PEG-IFN/RBV, although the taribavirin group's SVR was lower (38% vs. 52%) 78.

New combinations with and without interferon hold promise.

The task of developing novel therapeutic agents and combinations is to enhance the virological response, reduce the duration of therapy, and provide interferon-free treatment. It will be necessary to develop new therapies assessed using a number of metrics, including cost to the patient and society, reductions in side effects, enhanced treatment simplicity and pill burden, and advances in efficacy beyond the new benchmark of PI/PEG-IFN/RBV response. Interferon-free regimens have the potential to become accessible in a few years, which would reduce side effects and make treatment for those who are intolerant to interferon possible . Though quadruple therapy with two DAAs plus PEG-IFN/RBV has been shown to improve outcomes for patients with multiple poor treatment response predictors (e.g., cirrhosis, genotype-1 infection, high HCV viral load, and previous treatment non-response), there may still be a selective role for IFN. With these challenging patients, the rise in effectiveness may surpass rises in toxicity and complexity. Incremental modifications to the present triple therapy (PI/PEG-IFN/RBV) are another area where combination therapy is likely to improve in the coming years, as newer once-daily protease inhibitors replace boceprevir and telaprevir.

Treatment without interferon

IFN-free therapy combinations in various categories have been the subject of several investigations GS-7977 and daclatasvir are probably going to be two of the medicines in the first IFN-free regimens. In a research including NS5B polymerase (GS-7977) and ribavirin, treatment-naïve, genotype-2/-3 patients treated 40 individuals for 12 weeks, with PEG-IFN being randomly given for varying lengths of time or not at all 51. All subjects, regardless of PEG-IFN treatment, obtained an RVR and SVR. There were no instances of viral breakthrough and the same viral kinetics in the IFN-free arm, indicating that the combination has a strong barrier to resistance. All ten genotype-2/-3 patients who received GS-7977 monotherapy for 12 weeks experienced an end-of-treatment response. But four of them relapsed within four weeks after ending their treatment, consistently RBV is required in IFN-free regimens 51. Among genotype-1 null responders who were more difficult to treat, GS-7977 plus RBV for 12 weeks showed a 100% response at the end of treatment (n = 10). Nevertheless, within four weeks of ending treatment, nine out of ten relapsed 52. PEG-IFN, more DAA drugs, or extended DAA therapy may be necessary for previous null responders. Asynartetic, an NS3 protease inhibitor, and daclatasvir, an NS5A polymerase inhibitor, were investigated in a phase II therapy trial for genotype-1 non-responders without cirrhosis. Participants were randomized to receive PEG-IFN/RBV or no PEG-IFN/RBV 58. Of the 11 non-responders in the IFN-free group, 4/11 had an SVR, 1/11 relapsed following the conclusion of treatment due to undetectable HCV RNA, and 6/11 experienced viral breakout during therapy. When Looking at the genotype-1 subtype, only 2/9 genotype-1a patients and both genotype-1b infected patients (n = 2) had an SVR. Patients experiencing virological failure had mutations that conferred resistance against both NS5A and NS3 drugs. It's unknown how those mutations will impact treatment down the road. A small Japanese cohort (n = 10) with HCV genotype-1b and IL28B favorable experienced null responders to the same IFN-free medication combination after 24 weeks, and it was shown to have a 100% SVR 79. These preliminary findings imply that variations in genotype-1 subtype will affect the efficacy of IFN-free therapy.

Therapy in quadruples

In a phase II research involving PEG-IFN and RBV in conjunction with asunaprevir and daclatasvir, exceptionally high SVR rates were attained in a group of null responders 58 HCV RNA was not detectable during therapy in genotype-1 non-responders without cirrhosis who had received treatment. SVR response was 10/10, 9/10, and 9/10 at 12, 24, and 48 weeks, respectively. According to these findings, individuals who respond poorly to IFN may benefit greatly from triple therapy, which would have dramatically improved SVR rates compared to conventional therapy, which would have been expected to provide less than 10% SVR.

Conclusion:

2011 marked a turning point in the development of HCV therapies as it saw the approval of the first DAA and the demonstration of the viability of curing HCV without the need for IFN therapy 1. In order to improve treatment side effects and enable individuals with major psychiatric co-morbidities to get treatment for the first time, challenges still need to be addressed in the development of long-lasting, effective, IFN-free regimens that do not encourage HCV resistance. Currently, 80, 81 few drug injectors—the population most at risk of HCV infection—receive HCV treatment. More individuals may receive therapy overall, and injectable drug users in particular, if improved regimens have fewer side effects and last shorter. The therapy of HCV is rapidly changing, and emerging medication classes and agents will enhance it intricacy in the near future. Increasing treatment adoption among drug injectors has the potential to lower HCV prevalence in this high-risk population, in addition to the personal benefits of eradicating HCV 82, 83. The multitude of patients afflicted with HCV infection should find optimism in the swift advancements, achievements achieved thus far, and the quantity of HCV agents currently under research.

Conflict of interest : None

References:

1. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366: 273–275.doi: https://doi.org/10.1056/NEJMe1113272
View at Google Scholar | View at Publisher
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529–538.
View at Google Scholar | View at Publisher
3. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74–81.doi: https://doi.org/10.1111/j.1478-3231.2008.01934.x
View at Google Scholar | View at Publisher
4. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271–278.doi: https://doi.org/10.7326/0003-4819-156-4-201202210-00004
View at Google Scholar | View at Publisher
5. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237–44. https://doi.org/1053/jhep.2002.36810
View at Google Scholar | View at Publisher
6. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8: 212–223. https://doi.org/10.1038/nrgastro.2011.21
View at Google Scholar | View at Publisher
7. Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am 2010; 39: 649–658.
View at Google Scholar | View at Publisher
8. Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in theoptimal clinical management of chronic hepatitis C. Hepatol 2009; 50: 402–11.
View at Google Scholar | View at Publisher
9. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889–900. https://doi.org/10.1093/cid/cir076
View at Google Scholar | View at Publisher
10. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 265–274.
View at Google Scholar | View at Publisher
11. Doyle JS, Sacks-Davis R, Hellard ME. Acute hepatitis C infection: new approaches to surveillance, treatment and prevention. Curr Hepatitis Rep 2012; doi: https://doi.org/10.1007/s11901-012-0143-5 .
View at Google Scholar | View at Publisher

12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982. https://doi.org/10.1056/NEJMoa020047
View at Google Scholar | View at Publisher
13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
View at Google Scholar | View at Publisher
14. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action ofribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002–1009. https://doi.org/10.1053/jhep.2002.32672
View at Google Scholar | View at Publisher
15. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.
View at Google Scholar | View at Publisher
16. Holmes JA, Sievert W, Thompson AJ. IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. Biomark Med 2011; 5: 461–478. https://doi.org/10.2217/bmm.11.47
View at Google Scholar | View at Publisher
17. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA https://doi.org/10.1053/j.gastro.2010.04.013
View at Google Scholar | View at Publisher
18. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lotsch J, Berg T. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415–421. doi: https://doi.org/10.1016/j.jhep.2010.07.041
View at Google Scholar | View at Publisher
19. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32: 2117–2138. https://doi.org/10.1016/S0149-2918(11)00022-1
View at Google Scholar | View at Publisher
20. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634–651.
View at Google Scholar | View at Publisher
21. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245–264. https://doi.org/10.1016/j.jhep.2011.02.023
View at Google Scholar | View at Publisher
22. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600–609. https://doi.org/10.1053/jhep.2003.50106
View at Google Scholar | View at Publisher
23. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–652. https://doi.org/10.1053/jhep.2003.50364
View at Google Scholar | View at Publisher
24. Camma C, Cabibbo G, Bronte F, Enea M, Licata A, Attanasio M, Andriulli A, Craxi A. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. J Hepatol 2009; 51: 675–681. https://doi.org/10.1016/j.jhep.2009.06.018
View at Google Scholar | View at Publisher
25. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528–540. https://doi.org/10.7326/0003-4819-150-8-200904210-00007
View at Google Scholar | View at Publisher
26. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Goncales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618–1628. https://doi.org/10.1053/j.gastro.2009.01.039
View at Google Scholar | View at Publisher
27. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438–450. https://doi.org/10.1056/NEJMoa040842
View at Google Scholar | View at Publisher
28. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561–573. https://doi.org/10.1086/600304
View at Google Scholar | View at Publisher
29. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, Van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM. Effective treatment of injecting drug users with recently acquired hepatitis C virus Infection. Gastroenterology 2010; 138: 123–135.
View at Google Scholar | View at Publisher
30. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis Cvirus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979–1998. https://doi.org/10.1053/j.gastro.2007.03.116
View at Google Scholar | View at Publisher
31. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nature reviews. Microbiology 2007; 5: 453–463.
View at Google Scholar | View at Publisher
32. Jazwinski AB, Muir AJ. Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterol Clin North Am 2011; 40: 481–494.

View at Google Scholar | View at Publisher

33. Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol 2010; 3: 191–202. *https://doi.org/10.1177/1756283X10363055*
View at Google Scholar | View at Publisher
34. Lee LY, Tong CY, Wong T, Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 2012; 66: 342–355. *https://doi.org/10.1111/j.1742-1241.2012.02895.x*
View at Google Scholar | View at Publisher
35. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–1206.
View at Google Scholar | View at Publisher
36. Foote BS, Spooner LM, Belliveau PP. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother 2011; 45: 1085–1093. https://doi.org/10.1345/aph.1P744
View at Google Scholar | View at Publisher
37. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, KareyU, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709–1718. *https://doi.org/*10.1002/hep.23192
View at Google Scholar | View at Publisher
38. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767–1777.
View at Google Scholar | View at Publisher
39. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207–1217. *https://doi.org/10.1056/NEJMoa1009482*
View at Google Scholar | View at Publisher
40. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705–716.
View at Google Scholar | View at Publisher
41. Vierling JM. Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE Study. Hepatology 2011; 54 (Suppl. 1): A931.
View at Google Scholar | View at Publisher